Xtant Medical

Investors

Corporate Profile

Xtant Medical Holdings, Inc. (NYSE MKT: XTNT) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries.




Stock Quote
XTNT (Common Stock)
Price$0.47
Change (%) + 0.07 (17.50%)
Volume1,002,034
Data as of 02/27/17 4:02 p.m. ET
Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart


Recent News
DateTitle 
02/22/17Xtant Medical Announces Appointment of Carl O'Connell to Permanent CEO
BELGRADE, Mont., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the appointment of Carl O’Connell as the permanent CEO, effective February 17th, 2017. Mr. O'Connell previously served as president of Xtant since October of 2016 and was appointed as interim CEO on January 21st, 2017. Prior to joining Xtant Medical, Mr. O'Connell most recently served as the Vice P... 
01/23/17Xtant Medical CEO Dan Goldberger announces resignation
BELGRADE, Mont., Jan. 23, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today announced that on January 21, 2017, Dan Goldberger resigned as Chief Executive Officer and as a Director of the Company and its subsidiaries to pursue other interests. Current President Carl O’Connell will serve as interim CEO while the Company’s Board of Directors contempla... 
01/19/17XTNT Announces Issuance of PIK Notes
BELGRADE, Mont., Jan. 19, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today has announced the issuance of new convertible promissory notes on January 17, 2017 (the “New Notes”) to ROS Acquisition Offshore LP (“ROS”) and OrbiMed Royalty Opportunities II, LP (“OrbiMed”) for the following interest payments owed to them on January 15, 2017 (which were d... 
01/18/17XTNT Announces Closing of Registered Direct Offering
BELGRADE, Mont., Jan. 18, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today has announced the closing of a registered direct offering conducted without an underwriter or placement agent (the "Offering").  The Offering closed on January 17, 2017 and was with certain holders of its convertible promissory notes (“Indenture Notes”) to purchase a total o... 
More


Upcoming Events
There are currently no events scheduled.
More

Receive Email Alerts
Sign up to receive email alerts whenever Xtant Medical Holdings Inc posts new information to the site. Just enter your email address and click Submit.